Proactive Investors - Run By Investors For Investors

Alliance Pharma reports strong growth as it launches UK's first prescribed drug for morning sickness

Peter Butterfield, chief executive of Alliance Pharma plc (LON:APH), updates Proactive's Andrew Scott on the group's first half performance.

A strong performance from its portfolio of international brands boosted first-half sales.

Turnover rose by 10% to £54.5m (2017: £49.4m) with scar tissue treatment Kelo-cote seeing sales rise by 77% while eye supplement Macushield was 22% ahead of a year ago.

Since June they've also launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.

Sold under the brand name Xonvea, Diclectin was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full APH profile View Profile

Alliance Pharma plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use